CJC-1295 No DAC + Ipamorelin Blend (10mg Total)
5mg / 5mg Split
$90.00
CJC-1295 No DAC + Ipamorelin Blend (10mg Total)
5mg / 5mg Split | Dual-Pathway Growth Hormone Secretagogue Stack
The 4Balance Codex: The Synergistic "Signal and Gate" Amplifier for Pulsatile GH Dynamics.
Product Overview
This 10mg vial contains a precise, high-concentration blend of 5mg CJC-1295 No DAC (Mod GRF 1-29) and 5mg Ipamorelin.
This formulation represents a premier synergistic stack in peptide research. By simultaneously targeting two distinct receptors—the GHRH receptor and the ghrelin receptor (GHS-R1a)—this blend is designed to amplify the body’s natural, pulsatile release of growth hormone (GH) far beyond what either peptide can achieve individually. This multiplicative "1+1=3" effect makes it a staple tool for research focused on optimizing body composition, accelerating recovery kinetics, and investigating anti-aging pathways.
Format: Lyophilized Powder Blend Total Concentration: 10mg Composition: 5mg CJC-1295 No DAC / 5mg Ipamorelin
Mechanism of Action: The Dual-Pathway Synergy
Research establishes that this blend functions through complementary mechanisms to optimize the natural growth hormone pulse without disrupting natural rhythms.
The Signal (CJC-1295 No DAC): This GHRH analog binds to receptors in the pituitary gland, initiating the production of growth hormone. Unlike long-acting "DAC" variants that cause a continuous bleed, this "No DAC" version has a short half-life (~30 minutes), ensuring a physiological, pulsatile release that prevents pituitary desensitization.
The Gate (Ipamorelin): As a selective ghrelin mimetic, Ipamorelin binds to the GHS-R1a receptor to directly stimulate the release of stored GH. It is unique for its selectivity, achieving this release without triggering significant spikes in cortisol, prolactin, or appetite, distinguishing it from older secretagogues like GHRP-6.
The Synergy: When administered together, CJC-1295 provides the production signal, while Ipamorelin opens the gate for release. Comparative research suggests this combination creates a multiplier effect on resulting IGF-1 levels, the primary mediator of anabolic effects in the body.
Research-Observed Benefits
In controlled laboratory settings, the synergistic pairing of a GHRH analog and a selective secretagogue has been associated with a wide range of physiological improvements:
Maximized GH Secretion: Significantly enhances both the amplitude and duration of growth hormone pulses.
Muscle Hypertrophy: Supports increased protein synthesis and nitrogen retention necessary for lean tissue growth.
Accelerated Lipolysis: Promotes the mobilization and breakdown of adipose tissue (body fat) for energy.
Enhanced Recovery: Speeds up tissue repair and reduces inflammation markers following injury or acute stress.
Sleep Optimization: Research indicates potential improvements in restorative Stage 4 (Deep) and REM sleep cycles.
Selectivity and Safety Profile in Research
Clinical trials on Ipamorelin have demonstrated its high specificity, showing it can elevate plasma growth hormone levels effectively without the "spillover" effects on ACTH (cortisol) and prolactin common with other GHRPs. This makes the blend a preferred choice for research requiring a "clean" endocrine profile.
Technical Specifications
Appearance: White to off-white lyophilized powder
Purity: >99% (HPLC Verified)
Solubility: Water-soluble (Requires reconstitution with bacteriostatic water)
Storage: Store lyophilized vial at -20°C for long-term stability, away from direct sunlight.
Key References
Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism.
Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology.
Anderson, et al. (2001). Growth hormone secretion: molecular and cellular mechanisms and in vivo approaches. Endocrine Reviews.
DISCLAIMER: FOR LABORATORY RESEARCH USE ONLY. This product is a lyophilized peptide blend intended strictly for in-vitro and in-vivo research and development in a laboratory setting. It is not approved by the FDA for human consumption, medical treatment, or therapeutic use. Not for veterinary use. Buyer assumes all responsibility for applicable regulations and appropriate use in a research setting.
